About Baricitinib Phase 3 Trials Lilly and Incyte conducted four pivotal phase 3 clinical trials of baricitinib in patients with moderately-to-severely active rheumatoid arthritis to support regulatory submission in most countries. An additional phase 3 study was initiated to support clinical development in China. The clinical trial program includes a wide range of patients including those who are methotrexate-naive, inadequate responders to methotrexate, inadequate responders to conventional disease-modifying anti-rheumatic drugs, or inadequate responders to TNF inhibitors. Patients completing any of the five phase 3 studies can enroll in a long-term extension study. For additional information on this clinical trial program, please visit www.clinicaltrials.gov [http://www.clinicaltrials.gov/].
About Incyte Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics for oncology and inflammation. For additional information on Incyte, please visit the Company's web site at www.incyte.com [http://www.incyte.com/].
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com [http://www.lilly.com/] and newsroom.lilly.com/social-channels [http://newsroom.lilly.com/social-channels].
*The brand listed is a trademark of AbbVie and not a trademark of Eli Lilly and Company. The maker of this brand is not affiliated with and does not endorse Eli Lilly and Company or its products.
**Safety data are reported for patients receiving initial assigned treatment and prior to any rescue or switching.
(P--LLY)
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about baricitinib as a potential treatment for patients with rheumatoid arthritis and reflects Lilly and Incyte's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results will be consistent with study findings to-date, or that baricitinib will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's Form 10-K and 10-Qfilings with the United States Securities and Exchange Commission. Except as required by law, Lilly and Incyte undertake no duty to update forward-looking statements to reflect events after the date of this release.
(i) American College of Rheumatology, Rheumatoid Arthritis, http://www.rheumatology.org/practice/cli... [http://www.rheumatology.org/practice/cli...] (Accessed: October 20, 2015)
(ii) Hand Clinics, Advances in the Medical Treatment of Rheumatoid Arthritis,http://www.ncbi.nlm.nih.gov/pmc/articles... [http://www.ncbi.nlm.nih.gov/pmc/articles...] (Accessed: October 20, 2015)
(iii) WHO [http://www.who.int/chp/topics/rheumatic/...] Global Burden of Disease Report, (table 7, page 32) 2004, http://www.who.int/healthinfo/global_bur... [http://www.who.int/healthinfo/global_bur...] (Accessed October 20, 2015)
(iv) Arthritis Foundation, Medications for Rheumatoid Arthritis, http://www.arthritistoday.org/about-arthritis/types-of-arthr... [http://www.arthritistoday.org/about-arthritis/types-of-arthr...] (Accessed: October 20, 2015)
Refer to:Celeste Stanley; celeste_stanley@lilly.com[mailto:celeste_stanley@lilly.com]; +1-317-626-8896 (media) Phil Johnson; johnson_philip_l@lilly.com[mailto:johnson_philip_l@lilly.com]; +1-317-655-6874 (investors)Michael Booth, DPhil; mbooth@incyte.com[mailto:mbooth@incyte.com]; +1-302-498-5914 (Incyte)
Web site: http://www.incyte.com//http://www.lilly....
